Epsilon Healthcare Limited (EPN) Fair Value & Analysis
Healthcare · AU · Market cap A$8.9M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0300 to A$0.0214 (−28.6%) since Jun 24, 2026. Share price −8.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0190 – A$0.0380 · fair‑value band A$0.0193 – A$0.0240 · the A$0.0220 price screens above the A$0.0214 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Epsilon Healthcare Limited (EPN) currently trades at A$0.0220, while our model-based Fair Value estimate is A$0.0214 — implying the stock looks roughly 2.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Epsilon Healthcare Limited generated revenue of A$9.4M at a net margin of -13.6%. Revenue grew 119.4% year over year. Net debt stands at A$13.9M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Epsilon Healthcare Limited, together with its subsidiaries, engages in the healthcare business in Australia. The company operates in three segments, Contract Development and Manufacturing Activities, Telehealth Medical Practice Services, and Pharmacy Services. It is involved in the healthcare and clinics operation; pharmaceutical contract development and manufacturing; development and manufacturing of active pharmaceutical ingredients and finished formulation; and provision of pharmacy services and patient care. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Southport, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Epsilon Healthcare Limited reported revenue of A$9.4M in FY2025 versus A$5.5M in FY2021, a compound +14.3%/yr. Reported net income was −A$2.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,747 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Epsilon Healthcare Limited (EPN) undervalued?
What is the fair value of EPN?
What is the quality score of EPN?
What is the revenue of Epsilon Healthcare Limited (EPN)?
What is the net profit margin of EPN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.